Does the media favor AEHR or TRNS?

In the previous week, Aehr Test Systems had 31 more articles in the media than Transcat. MarketBeat recorded 35 mentions for Aehr Test Systems and 4 mentions for Transcat. Transcat's average media sentiment score of 0.90 beat Aehr Test Systems' score of 0.55 indicating that Transcat is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aehr Test Systems 11 Very Positive mention(s) 4 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Positive Transcat 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, TRNS or ALMR?

Transcat has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Transcat $331.88M 2.42 $5.38M $0.58 148.43 Alamar Biosciences $87.16M 19.02 -$120.60M -$1.74 N/A

Does the media refer more to TRNS or ALMR?

In the previous week, Transcat had 3 more articles in the media than Alamar Biosciences. MarketBeat recorded 4 mentions for Transcat and 1 mentions for Alamar Biosciences. Transcat's average media sentiment score of 0.90 beat Alamar Biosciences' score of 0.67 indicating that Transcat is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Transcat 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ALNT or TRNS?

Allient has higher revenue and earnings than Transcat. Allient is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allient $554.48M 2.66 $22.03M $1.43 60.57 Transcat $331.88M 2.42 $5.38M $0.58 148.43

Is ALNT or TRNS more profitable?

Allient has a net margin of 4.25% compared to Transcat's net margin of 1.62%. Allient's return on equity of 12.47% beat Transcat's return on equity. Company Net Margins Return on Equity Return on Assets Allient 4.25% 12.47% 6.37% Transcat 1.62% 5.84% 3.78%

Does the media favor ALNT or TRNS?

In the previous week, Transcat had 2 more articles in the media than Allient. MarketBeat recorded 4 mentions for Transcat and 2 mentions for Allient. Allient's average media sentiment score of 1.10 beat Transcat's score of 0.90 indicating that Allient is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allient 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Transcat 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TRNS or EYPT?

In the previous week, Eyepoint Pharmaceuticals had 4 more articles in the media than Transcat. MarketBeat recorded 8 mentions for Eyepoint Pharmaceuticals and 4 mentions for Transcat. Transcat's average media sentiment score of 0.90 beat Eyepoint Pharmaceuticals' score of 0.32 indicating that Transcat is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Transcat 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eyepoint Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, TRNS or CTKB?

Transcat has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Transcat $331.88M 2.42 $5.38M $0.58 148.43 Cytek Biosciences $201.49M 2.94 -$66.54M -$0.57 N/A

Does the media favor TRNS or CTKB?

In the previous week, Transcat had 2 more articles in the media than Cytek Biosciences. MarketBeat recorded 4 mentions for Transcat and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.96 beat Transcat's score of 0.90 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Transcat 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytek Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Transcat (TRNS) Competitors

$86.09 -1.81 (-2.06%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$86.15 +0.06 (+0.07%)

As of 07/20/2026 04:10 PM Eastern

Compare

TRNS vs. AEHR, ALMR, ALNT, EYPT, and CTKB

Should you buy Transcat stock or one of its competitors? MarketBeat compares Transcat with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Transcat include Aehr Test Systems (AEHR), Alamar Biosciences (ALMR), Allient (ALNT), Eyepoint Pharmaceuticals (EYPT), and Cytek Biosciences (CTKB). These companies are all part of the "measuring and control equipment" industry.

How does Transcat compare to Aehr Test Systems?

Aehr Test Systems (NASDAQ:AEHR) and Transcat (NASDAQ:TRNS) are both computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Transcat has higher revenue and earnings than Aehr Test Systems. Aehr Test Systems is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aehr Test Systems	$50M	48.66	-$7.13M	-$0.24	N/A
Transcat	$331.88M	2.42	$5.38M	$0.58	148.43

Aehr Test Systems presently has a consensus price target of $117.50, indicating a potential upside of 51.89%. Transcat has a consensus price target of $105.50, indicating a potential upside of 22.55%. Given Aehr Test Systems' stronger consensus rating and higher possible upside, research analysts clearly believe Aehr Test Systems is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aehr Test Systems	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Transcat	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

69.7% of Aehr Test Systems shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 6.8% of Aehr Test Systems shares are owned by insiders. Comparatively, 2.8% of Transcat shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Aehr Test Systems has a beta of 3.17, indicating that its share price is 217% more volatile than the broader market. Comparatively, Transcat has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Transcat has a net margin of 1.62% compared to Aehr Test Systems' net margin of -14.25%. Transcat's return on equity of 5.84% beat Aehr Test Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aehr Test Systems	-14.25%	-4.48%	-3.90%
Transcat	1.62%	5.84%	3.78%

In the previous week, Aehr Test Systems had 31 more articles in the media than Transcat. MarketBeat recorded 35 mentions for Aehr Test Systems and 4 mentions for Transcat. Transcat's average media sentiment score of 0.90 beat Aehr Test Systems' score of 0.55 indicating that Transcat is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aehr Test Systems	11 Very Positive mention(s)	4 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Positive
Transcat	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Transcat beats Aehr Test Systems on 9 of the 16 factors compared between the two stocks.

How does Transcat compare to Alamar Biosciences?

Transcat (NASDAQ:TRNS) and Alamar Biosciences (NASDAQ:ALMR) are both small-cap measuring and control equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Transcat has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$331.88M	2.42	$5.38M	$0.58	148.43
Alamar Biosciences	$87.16M	19.02	-$120.60M	-$1.74	N/A

Transcat currently has a consensus target price of $105.50, indicating a potential upside of 22.55%. Alamar Biosciences has a consensus target price of $30.00, indicating a potential upside of 25.42%. Given Alamar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Alamar Biosciences is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Alamar Biosciences	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Transcat has a net margin of 1.62% compared to Alamar Biosciences' net margin of 0.00%. Transcat's return on equity of 5.84% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	1.62%	5.84%	3.78%
Alamar Biosciences	N/A	N/A	N/A

98.3% of Transcat shares are owned by institutional investors. 2.8% of Transcat shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Transcat had 3 more articles in the media than Alamar Biosciences. MarketBeat recorded 4 mentions for Transcat and 1 mentions for Alamar Biosciences. Transcat's average media sentiment score of 0.90 beat Alamar Biosciences' score of 0.67 indicating that Transcat is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Transcat	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Transcat beats Alamar Biosciences on 12 of the 16 factors compared between the two stocks.

How does Transcat compare to Allient?

Allient (NASDAQ:ALNT) and Transcat (NASDAQ:TRNS) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Allient presently has a consensus target price of $79.83, indicating a potential downside of 7.82%. Transcat has a consensus target price of $105.50, indicating a potential upside of 22.55%. Given Transcat's higher probable upside, analysts plainly believe Transcat is more favorable than Allient.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allient	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Transcat	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Allient has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, Transcat has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

61.6% of Allient shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 15.0% of Allient shares are owned by company insiders. Comparatively, 2.8% of Transcat shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Allient has higher revenue and earnings than Transcat. Allient is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allient	$554.48M	2.66	$22.03M	$1.43	60.57
Transcat	$331.88M	2.42	$5.38M	$0.58	148.43

Allient has a net margin of 4.25% compared to Transcat's net margin of 1.62%. Allient's return on equity of 12.47% beat Transcat's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allient	4.25%	12.47%	6.37%
Transcat	1.62%	5.84%	3.78%

In the previous week, Transcat had 2 more articles in the media than Allient. MarketBeat recorded 4 mentions for Transcat and 2 mentions for Allient. Allient's average media sentiment score of 1.10 beat Transcat's score of 0.90 indicating that Allient is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allient	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Transcat	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Allient beats Transcat on 12 of the 17 factors compared between the two stocks.

How does Transcat compare to Eyepoint Pharmaceuticals?

Transcat (NASDAQ:TRNS) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap measuring and control equipment companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

98.3% of Transcat shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 2.8% of Transcat shares are owned by company insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Transcat currently has a consensus price target of $105.50, suggesting a potential upside of 22.55%. Eyepoint Pharmaceuticals has a consensus price target of $43.75, suggesting a potential upside of 245.58%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Eyepoint Pharmaceuticals had 4 more articles in the media than Transcat. MarketBeat recorded 8 mentions for Eyepoint Pharmaceuticals and 4 mentions for Transcat. Transcat's average media sentiment score of 0.90 beat Eyepoint Pharmaceuticals' score of 0.32 indicating that Transcat is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Transcat	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eyepoint Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Transcat has a net margin of 1.62% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Transcat's return on equity of 5.84% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	1.62%	5.84%	3.78%
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

Transcat has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.73, suggesting that its share price is 73% more volatile than the broader market.

Transcat has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$331.88M	2.42	$5.38M	$0.58	148.43
Eyepoint Pharmaceuticals	$31.37M	33.84	-$231.96M	-$3.50	N/A

Summary

Transcat and Eyepoint Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Transcat compare to Cytek Biosciences?

Transcat (NASDAQ:TRNS) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap measuring and control equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

98.3% of Transcat shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 2.8% of Transcat shares are owned by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Transcat currently has a consensus target price of $105.50, suggesting a potential upside of 22.55%. Cytek Biosciences has a consensus target price of $5.69, suggesting a potential upside of 24.18%. Given Cytek Biosciences' higher possible upside, analysts clearly believe Cytek Biosciences is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Transcat has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$331.88M	2.42	$5.38M	$0.58	148.43
Cytek Biosciences	$201.49M	2.94	-$66.54M	-$0.57	N/A

Transcat has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

In the previous week, Transcat had 2 more articles in the media than Cytek Biosciences. MarketBeat recorded 4 mentions for Transcat and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.96 beat Transcat's score of 0.90 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Transcat	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Transcat has a net margin of 1.62% compared to Cytek Biosciences' net margin of -36.25%. Transcat's return on equity of 5.84% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	1.62%	5.84%	3.78%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

Summary

Transcat beats Cytek Biosciences on 11 of the 17 factors compared between the two stocks.

Get Transcat News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRNS vs. The Competition

Export

Metric	Transcat	INSTRU Industry	Computer Sector	NASDAQ Exchange
Market Cap	$821.05M	$3.25B	$37.81B	$12.28B
Dividend Yield	N/A	0.96%	3.15%	9.39%
P/E Ratio	148.43	71.35	168.48	23.94
Price / Sales	2.42	3.87	597.02	91.94
Price / Cash	18.83	27.49	43.51	47.25
Price / Book	2.67	4.26	9.26	6.14
Net Income	$5.38M	$70.38M	$1.07B	$331.74M
7 Day Performance	-4.06%	1.73%	-2.13%	-1.81%
1 Month Performance	-7.31%	-2.68%	-1.76%	-1.44%
1 Year Performance	7.04%	60.67%	134.94%	16.33%

Transcat Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRNS Transcat	3.5738 of 5 stars	$86.09 -2.1%	$105.50 +22.5%	+5.9%	$821.05M	$331.88M	148.43	1,413
AEHR Aehr Test Systems	3.9528 of 5 stars	$69.34 +1.9%	$68.00 -1.9%	+413.3%	$2.17B	$58.97M	N/A	90	Analyst Upgrade Gap Up
ALMR Alamar Biosciences	2.9622 of 5 stars	$27.77 +1.4%	$30.00 +8.0%	N/A	$1.92B	$87.16M	N/A	222
ALNT Allient	3.928 of 5 stars	$87.83 +0.6%	$79.83 -9.1%	+117.5%	$1.48B	$554.48M	60.76	2,478	Positive News Gap Up
EYPT Eyepoint Pharmaceuticals	3.1464 of 5 stars	$14.30 +0.1%	$44.29 +209.8%	+21.5%	$1.20B	$31.37M	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRNS) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Transcat (TRNS) Competitors

TRNS vs. AEHR, ALMR, ALNT, EYPT, and CTKB

How does Transcat compare to Aehr Test Systems?

Summary

How does Transcat compare to Alamar Biosciences?

Summary

How does Transcat compare to Allient?

Summary

How does Transcat compare to Eyepoint Pharmaceuticals?

Summary

How does Transcat compare to Cytek Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRNS vs. The Competition

Transcat Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Transcat (TRNS) Competitors

TRNS vs. AEHR, ALMR, ALNT, EYPT, and CTKB

How does Transcat compare to Aehr Test Systems?

Which has higher valuation and earnings, AEHR or TRNS?

Do analysts recommend AEHR or TRNS?

Do institutionals and insiders believe in AEHR or TRNS?

Which has more risk & volatility, AEHR or TRNS?

Is AEHR or TRNS more profitable?

Does the media favor AEHR or TRNS?

Summary

How does Transcat compare to Alamar Biosciences?

Which has higher valuation and earnings, TRNS or ALMR?

Do analysts prefer TRNS or ALMR?

Is TRNS or ALMR more profitable?

Do institutionals and insiders believe in TRNS or ALMR?

Does the media refer more to TRNS or ALMR?

Summary

How does Transcat compare to Allient?

Do analysts rate ALNT or TRNS?

Which has more volatility & risk, ALNT or TRNS?

Do institutionals and insiders believe in ALNT or TRNS?

Which has preferable valuation and earnings, ALNT or TRNS?

Is ALNT or TRNS more profitable?

Does the media favor ALNT or TRNS?

Summary

How does Transcat compare to Eyepoint Pharmaceuticals?

Do insiders & institutionals hold more shares of TRNS or EYPT?

Do analysts prefer TRNS or EYPT?

Does the media refer more to TRNS or EYPT?

Is TRNS or EYPT more profitable?

Which has more risk and volatility, TRNS or EYPT?

Which has preferable earnings and valuation, TRNS or EYPT?

Summary

How does Transcat compare to Cytek Biosciences?

Do insiders and institutionals have more ownership in TRNS or CTKB?

Do analysts rate TRNS or CTKB?

Which has higher earnings and valuation, TRNS or CTKB?

Which has more risk & volatility, TRNS or CTKB?

Does the media favor TRNS or CTKB?

Is TRNS or CTKB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRNS vs. The Competition

Transcat Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools